Good news! BioEngine won the honorable award of BioCon Awards for the best Chinese alternative solution of the year

On the evening of September 6, BioCon Awards Banquet, initiated by the organizing committee of BioCon Expo 2022, was held at Hangzhou International Expo Center. After several rounds of selection by the organizing committee, as well as public voting and rating by the delegates, BioEngine was awarded the "Honorable Award of the Best Chinese Alternative Solution of the Year" among many companies.

"BioCon Awards" aims to recognize and share the frontal, progressive, innovative, and top biotechnology forces in China and abroad in the past year, and aims to become the most influential and authoritative international biopharmaceutical awards in the biotechnology and pharmaceutical industry. The award fully reflects the industry's high recognition of the serum-free medium independent research and development achievements and the localization manufacturing level of BioEngine!

As the advocate and practitioner of "Intelligent Manufacturing in China" serum-free medium, BioEngine knows how to make domestic culture media with excellent quality and stable supply that Chinese biopharmaceutical companies dare to use, use well and rush to use is a question that Chinese culture media companies must think about. We firmly believe that the localization of culture media should be "Intelligent Manufacturing in China" based on sufficient domestic raw materials, strong independent R&D and innovation capabilities, and an international leading manufacturing management level. Based on the cutting-edge culture media factory in China, BioEngine can press the accelerator button for the localization of culture media with continuous independent R&D and innovation capability, professional and reliable service, and provide continuous and steady power for the development of biopharmaceuticals in China.

In the future, BioEngine will continue to work hard in the field of large-scale animal cell culture, lead the localization of culture media, and empower the Chinese biopharmaceutical industry to reduce costs and increase efficiency.